Medipost said Wednesday that it has acquired patents on its core production technology of Cartistem in the U.K., Germany, France, Italy, Spain and Switzerland.

The patent named “TSP-1, TSP-2, IL-17BR and HB-EGF associated with stem cell activities and applications thereof,” relates to a technology for preventing or treating cartilage damage, degeneration, deficiency, and degenerative arthritis. The patent also includes cord blood-derived mesenchymal stem cells expressing TSP-2 protein composition.

Medipost _{메디포스트} had previously won patents in the same six European countries for "Screening method for cartilage-differentiating cells and secretory proteins involved in the treatment of cartilage damage,” in 2015.

The company expects that both patents will be applicable for Cartistem production in Europe.

MediPost had acquired nine domestic and foreign patents related to stem cell treatment drugs this year and is actively involved in research and development (R&D) to secure future-oriented core technologies.